Cargando…
Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960150/ https://www.ncbi.nlm.nih.gov/pubmed/29776437 http://dx.doi.org/10.1186/s40001-018-0320-2 |
_version_ | 1783324535796269056 |
---|---|
author | Chen, Fei Liu, Fan Lu, Jingchao Yang, Xiuchun Xiao, Bing Jin, Yaqiong Zhang, Jie |
author_facet | Chen, Fei Liu, Fan Lu, Jingchao Yang, Xiuchun Xiao, Bing Jin, Yaqiong Zhang, Jie |
author_sort | Chen, Fei |
collection | PubMed |
description | BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction. METHODS: Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial. The development of CIN was occurrence at the 48 or 72 h after the procedure. The changes of serum creatinine (SCr), eGFR, and Cys-C within 72 h after the procedure were measured and compared. In vivo contrast medium (CM)-induced acute kidney injury (AKI) animal model was established, and CoQ10 plus TMZ was orally administrated to evaluate its renal protective effect. RESULTS: 150 patients with renal insufficiency were enrolled finally. CIN occurred in 21 (14.00%) of the 150 patients. 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01). No cardiac death occurred in this study. No side effects were observed after administration of CoQ10 and TMZ. In vivo test demonstrated that CoQ10 and TMZ could significantly reduce the concentration of blood urea nitrogen (BUN) and SCR induced by CM i.v. injection, as well as tubular pathological injuries. Meanwhile, CoQ10 and TMZ could significantly reduce the oxidation stress in kidneys from CM-AKI animals. CONCLUSION: CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization, and their effect may be due to its strong anti-oxidation effect. |
format | Online Article Text |
id | pubmed-5960150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59601502018-05-24 Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study Chen, Fei Liu, Fan Lu, Jingchao Yang, Xiuchun Xiao, Bing Jin, Yaqiong Zhang, Jie Eur J Med Res Research BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction. METHODS: Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial. The development of CIN was occurrence at the 48 or 72 h after the procedure. The changes of serum creatinine (SCr), eGFR, and Cys-C within 72 h after the procedure were measured and compared. In vivo contrast medium (CM)-induced acute kidney injury (AKI) animal model was established, and CoQ10 plus TMZ was orally administrated to evaluate its renal protective effect. RESULTS: 150 patients with renal insufficiency were enrolled finally. CIN occurred in 21 (14.00%) of the 150 patients. 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01). No cardiac death occurred in this study. No side effects were observed after administration of CoQ10 and TMZ. In vivo test demonstrated that CoQ10 and TMZ could significantly reduce the concentration of blood urea nitrogen (BUN) and SCR induced by CM i.v. injection, as well as tubular pathological injuries. Meanwhile, CoQ10 and TMZ could significantly reduce the oxidation stress in kidneys from CM-AKI animals. CONCLUSION: CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization, and their effect may be due to its strong anti-oxidation effect. BioMed Central 2018-05-18 /pmc/articles/PMC5960150/ /pubmed/29776437 http://dx.doi.org/10.1186/s40001-018-0320-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chen, Fei Liu, Fan Lu, Jingchao Yang, Xiuchun Xiao, Bing Jin, Yaqiong Zhang, Jie Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title | Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title_full | Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title_fullStr | Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title_full_unstemmed | Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title_short | Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
title_sort | coenzyme q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960150/ https://www.ncbi.nlm.nih.gov/pubmed/29776437 http://dx.doi.org/10.1186/s40001-018-0320-2 |
work_keys_str_mv | AT chenfei coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT liufan coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT lujingchao coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT yangxiuchun coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT xiaobing coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT jinyaqiong coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy AT zhangjie coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy |